Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Charles River Laboratories International, Inc. Common Stock (NY:CRL)

161.66 +3.66 (+2.31%)
Streaming Delayed Price Updated: 3:18 PM EST, Feb 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Charles River Laboratories International, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
Charles River Launches Rep/Cap Plasmids to Streamline Adeno-Associated Viral Vector Manufacturing
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
Charles River Laboratories to Present at J.P. Morgan Healthcare Conference
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
Charles River and Vertex Pharmaceuticals Reach Important Milestone in Cell Therapy Manufacturing Collaboration
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
Charles River Finalizes Agreement with CELLphenomics, Expanding 3D In Vitro Services for Cancer Therapy Drug Screening
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
Charles River and Genetic Cures for Kids Announce Gene Therapy Manufacturing Collaboration
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
Charles River Laboratories to Present at Evercore ISI Investor Conference
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
Charles River Introduces CliniPrime Cryopreserved Leukopaks, Expanding Suite of GMP-Compliant Cellular Products
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
Charles River and Aitia Enter Strategic Agreement to Utilize Logica in Discovery Programs for Neurodegenerative Diseases and Oncology
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
Charles River Laboratories’ Industry Experts to Present Advanced Modalities at Neuroscience 2023
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
Charles River Laboratories Announces Third-Quarter 2023 Results
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
Charles River Launches Real-Time Research Model Ordering, Introducing an Important Digital Innovation to Research Models & Services Business
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
Charles River Laboratories Schedules Third-Quarter 2023 Earnings Release and Conference Call
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
Charles River Laboratories Provides Access to Relevant, Well-Characterized Pediatric PDX Collection for Oncology Research
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
Charles River Laboratories Achieves 90% Renewable Electricity Globally, Announces Progress on Environmental Goals
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
Charles River Unveils Lentivation Platform to Expedite LVV-based Gene Therapy Manufacturing
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
Charles River Announces Opening of RightSourceSM Laboratory, Supporting Stevenage Biocluster
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
Charles River Laboratories International, Inc. (NYSE: CRL) Long Term Investor Alert: Investigation of Potential Wrongdoing ↗
San Diego, CA -- (SBWIRE) -- 09/22/2023 -- Certain directors of Charles River Laboratories International, Inc are under investigation concerning potential breaches of fiduciary duties. 
Via SBWire
News headline image
Charles River Laboratories to Host Virtual Investor Day
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
Charles River and Related Sciences Enter Multi-Program Collaboration to Pursue AI-Enabled Drug Discovery Utilizing Logica
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
Charles River Laboratories to Present at Baird and Morgan Stanley Conferences
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
Charles River and PathoQuest Announce Publication of a Head-to-Head Study Validating Proprietary Next Generation Sequencing Viral Safety Assay as a Reliable In Vitro Alternative to Animal Testing Methods
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
Charles River Laboratories Announces Plasmid Manufacturing Collaboration with Fondazione Telethon
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
CHARLES RIVER ALERT: Bragar Eagel & Squire, P.C. is Investigating Charles River Laboratories International, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
News headline image
Charles River Laboratories Announces Second-Quarter 2023 Results
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
Charles River Laboratories Expands Access to AAALAC-Accredited, Turnkey Research Space in Key Markets
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
Charles River Laboratories Schedules Second-Quarter 2023 Earnings Release and Conference Call
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Charles River Laboratories International, Inc. (CRL)
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
CRL FINAL DEADLINE TOMORROW: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Charles River Laboratories International, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important July 18 Deadline in Securities Class Action – CRL
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Stem, Disney, Charles River, and Virtu and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
CRL DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Charles River Laboratories International, Inc. Investors to Secure Counsel Before Important July 18 Deadline in Securities Class Action - CRL
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Law Enforcement Lawsuit
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.